Fulgent Genetics Reports Q1 2025: Sales Up 16%, Posts GAAP Loss of $11.5M, EPS at ($0.37)

Reuters

2025/05/02

Fulgent Genetics Reports Q1 2025: Sales Up 16%, Posts GAAP Loss of $11.5M, EPS at ($0.37)

Fulgent Genetics Inc. reported its first-quarter 2025 financial results, showcasing a core revenue growth of 16% year-over-year, amounting to $73.5 million. The company recorded a non-GAAP income of $1.2 million, translating to $0.04 per share. However, the GAAP results showed a loss of $11.5 million, reflecting a challenging period for the company. Fulgent maintained its full-year 2025 core revenue guidance at $310 million. The company ended the quarter with $814.6 million in cash, cash equivalents, restricted cash, and investments in marketable securities, equating to a cash per share value of $26.60. Fulgent remains optimistic about its growth prospects, bolstered by its Laboratory Services business and ongoing progress in its Therapeutic Development pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250501738173) on May 02, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2532140918"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532140918\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2532140918?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532140918","market":"nz","top_or_hot":-1,"title":"Fulgent Genetics Reports Q1 2025: Sales Up 16%, Posts GAAP Loss of $11.5M, EPS at ($0.37)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fulgent Genetics Reports Q1 2025: Sales Up 16%, Posts GAAP Loss of $11.5M, EPS at ($0.37)\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics Inc.</a> reported its first-quarter 2025 financial results, showcasing a core revenue growth of 16% year-over-year, amounting to $73.5 million. The company recorded a non-GAAP income of $1.2 million, translating to $0.04 per share. However, the GAAP results showed a loss of $11.5 million, reflecting a challenging period for the company. Fulgent maintained its full-year 2025 core revenue guidance at $310 million. The company ended the quarter with $814.6 million in cash, cash equivalents, restricted cash, and investments in marketable securities, equating to a cash per share value of $26.60. Fulgent remains optimistic about its growth prospects, bolstered by its Laboratory Services business and ongoing progress in its Therapeutic Development pipeline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250501738173) on May 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fulgent Genetics Reports Q1 2025: Sales Up 16%, Posts GAAP Loss of $11.5M, EPS at ($0.37)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFulgent Genetics Reports Q1 2025: Sales Up 16%, Posts GAAP Loss of $11.5M, EPS at ($0.37)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-02 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fulgent Genetics Reports Q1 2025: Sales Up 16%, Posts GAAP Loss of $11.5M, EPS at ($0.37)\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics Inc.</a> reported its first-quarter 2025 financial results, showcasing a core revenue growth of 16% year-over-year, amounting to $73.5 million. The company recorded a non-GAAP income of $1.2 million, translating to $0.04 per share. However, the GAAP results showed a loss of $11.5 million, reflecting a challenging period for the company. Fulgent maintained its full-year 2025 core revenue guidance at $310 million. The company ended the quarter with $814.6 million in cash, cash equivalents, restricted cash, and investments in marketable securities, equating to a cash per share value of $26.60. Fulgent remains optimistic about its growth prospects, bolstered by its Laboratory Services business and ongoing progress in its Therapeutic Development pipeline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250501738173) on May 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FLGT","symbol_name":"Fulgent Genetics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nNDL9JN0ZB:1","article_id":"2532140918","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532140918","pubTimestamp":1746183628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Fulgent Genetics Inc. reported its first-quarter 2025 financial results, showcasing a core revenue growth of 16% year-over-year, amounting to $73.5 million. The company recorded a non-GAAP income of $1.2 million, translating to $0.04 per share. However, the GAAP results showed a loss of $11.5 million, reflecting a challenging period for the company. Fulgent maintained its full-year 2025 core revenue guidance at $310 million. The company ended the quarter with $814.6 million in cash, cash equivalents, restricted cash, and investments in marketable securities, equating to a cash per share value of $26.60. Fulgent remains optimistic about its growth prospects, bolstered by its Laboratory Services business and ongoing progress in its Therapeutic Development pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes on","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"FLGT":"Fulgent Genetics Inc."},"translate_title":"Fulgent Genetics报告2025年第一季度：销售额增长16%，GAAP亏损1,150万美元，每股收益为(0.37美元)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FLGT":0.9},"content_text":"Fulgent Genetics Reports Q1 2025: Sales Up 16%, Posts GAAP Loss of $11.5M, EPS at ($0.37)\n    \n\nFulgent Genetics Inc. reported its first-quarter 2025 financial results, showcasing a core revenue growth of 16% year-over-year, amounting to $73.5 million. The company recorded a non-GAAP income of $1.2 million, translating to $0.04 per share. However, the GAAP results showed a loss of $11.5 million, reflecting a challenging period for the company. Fulgent maintained its full-year 2025 core revenue guidance at $310 million. The company ended the quarter with $814.6 million in cash, cash equivalents, restricted cash, and investments in marketable securities, equating to a cash per share value of $26.60. Fulgent remains optimistic about its growth prospects, bolstered by its Laboratory Services business and ongoing progress in its Therapeutic Development pipeline.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250501738173) on May 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}